Top Markets
#1 Black Phoenix Black Phoenix +354.68%
#2 Glidr Glidr +84.34%
#3 Akedo Akedo +81.44%
#4 Gold Park Gold Park +61.34%
#5 OpenEden OpenEden +47.65%
#6 Acurast Acurast +33.48%
#7 BasedHype BasedHype +27.22%
#8 Cryptopia Cryptopia +21.54%
#9 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +20.03%
#10 Avantis Avantis +19.86%
Coin of the day
Black Phoenix Black Phoenix
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Solvonis Therapeutics plc Solvonis Therapeutics plc

Solvonis Therapeutics plc

SVNS
Rang in Aktien #40468
Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January... Graft Polymer (UK) Plc, set to become Solvonis Therapeutics plc in January 2025, is dedicated to the research and development of advanced polymer modification technologies and techniques. Its operations span the United Kingdom, Slovenia, and across Europe. The company offers a diverse portfolio of specialized products: GRAFTABOND: A line of graft/block copolymers designed to robustly combine various polymers with materials such as fiberglass, carbon fiber, mineral and natural fillers, and even mixed polymer waste. GRAFTALEN: These are reactive solid super-concentrates engineered to enhance polyolefin rheology, boost e-modulus, act as chain extenders for PET/PBT, and serve as AOX masterbatches. GRAFTAPOR: Comprising porous polymer-carriers, this line is specifically developed for applications involving liquid chemicals. GRAFTAMID: This series includes high-temperature elastomers, based on nanostructured polyolefin-polyamide alloys. They function as advanced hardening modifiers within polyamide compounds or as standalone components in hot melt adhesive formulations. GRAFTAKIT: Offering reactive liquid or solid super-concentrates embedded in polymeric porous media, GRAFTAKIT is used to optimize reaction extrusion and the modification of compounds. GRAFTALLOY: A range of polymer-polymer nano-alloys crafted to significantly improve abrasion and temperature resistance, boost impact strength, and reduce friction. GRAFTASYNT: This line encompasses synthetic products, notably including halogen-free flame retardants. GRAFTAMER: An innovative smart polymer characterized by thermo-reversible crosslinking, self-hardening, self-healing properties, and shape memory capabilities. The company was founded in 2017 and maintains its headquarters in London, United Kingdom.
Aktienkurs
$0.00204105
Marktkapitalisierung
$138.92K
Veränderung (1 Tag)
5.63%
Veränderung (1 Jahr)
-60.44%
Land
GB
Handel Solvonis Therapeutics plc (SVNS)

Kategorie

Industrials
Operative Marge für Solvonis Therapeutics plc (SVNS)
Operative Marge zum 2026 TTM: 0.00%
Laut den neuesten Finanzberichten und dem Aktienkurs von Solvonis Therapeutics plc beträgt die aktuelle operative Marge (TTM) 0.00%. Am Ende des Jahres 2026 lag die operative Marge bei 0.00%.
Historie der operativen Marge von Solvonis Therapeutics plc von 2026 bis 2026
Operative Marge zum Jahresende
Jahr Operative Marge ändert
Nicht genügend Daten für die angegebenen Daten.
Operative Marge vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Operative Marge Differenz der operativen Marge Land
Lam Research Corp. R Lam Research Corp. R
Lam Research Corp. R
LAR0.DE
0.00% -
US
Siemens AG Siemens AG
Siemens AG
SIE.DE
11.56% -
DE
Schneider Electric S.E. Schneider Electric S.E.
Schneider Electric S.E.
SU.PA
0.00% -
FR
Siemens Energy AG Siemens Energy AG
Siemens Energy AG
ENR.DE
0.00% -
DE
Parker-Hannifin Corporation Parker-Hannifin Corporation
Parker-Hannifin Corporation
PH.US
20.87% -
US
Was ist die operative Marge eines Unternehmens?
Die operative Marge ist ein wichtiger Indikator zur Bewertung der Rentabilität eines Unternehmens. Höhere operative Margen sind in der Regel besser, da sie zeigen, dass ein Unternehmen seine Produkte oder Dienstleistungen mit deutlichem Gewinn über den Produktionskosten verkauft. Die operative Marge wird berechnet, indem der Gewinn des Unternehmens durch seinen Umsatz geteilt wird.